Table 1.

Correlation of NY-ESO-1 antibody at baseline (before treatment) with clinical course following anti–CTLA-4 treatment

Response at wk 24	Total (%)	NY-ESO-1 seronegative	NY-ESO-1 seropositive
Clinical benefit	48 (34.3)	36 (30.5)	12 (54.6)
Complete response	4 (2.9)	3	1
Partial response	14 (10.0)	10	4
Stable disease	30 (21.4)	23	7
No clinical benefit	92 (65.7)	82 (69.5)	10 (45.4)
Total	140	118	22

Patients seropositive for NY-ESO-1 are more likely to experience disease control than seronegative patients [P = 0.0481, RR = 1.8 (1.1–2.9), two-tailed Fisher test].